Background. Genetic polymorphism of renin-angiotensin-aldosterone system affects the pathogenesis of hypertension (HTN), ischemic heart disease (IHD) and heart failure (HF). The purpose of our study is to analyze A/G renin genetic polymorphism in heart failure patients.
INTRODUCTION
Genetic predisposition in cardiovascular pathology is the consequence of the interaction between genetic polymorphism and external risk factors. At the same time, the presence of the genetic mutations influence the therapeutic and diet response in patients diagnosed with cardiovascular disease. Genetic mutations of renin-angiotensinaldosterone (RAS) system (renin, angiotensinogen, angiotensin II converting enzyme, angiotensin II receptors type 1 and 2) represent a great interest for many researchers because of their key role in pathogenesis of chronic heart disease. RAS system is activated during the last stages of chronic heart failure and leads to hydro saline retention with an increase of cardiac input. Discovered 100 years ago, renin is one of the most important hormones involved in the pathogenesis of high blood pressure, as well as of other cardiac diseases. Secreted by the juxtaglomerular renal cells, renin is an aspartyl protease which carries out the conversion of angiotensinogen released by the liver to angiotensin I. Renin is an aspartyl protease which carries out the conversion of angiotensinogen released by the liver to angiotensin I. Angiotensin I is subsequently converted to angiotensin II by the angiotensin converting enzyme found in the lungs. Also, it was reported that non-ACE pathways are involved [1, 2] . Excessive renin secretion causes high angiotensin II and aldosterone plasma levels with vasoconstriction and hydro saline retention effects, both having a significant contribution in the progression of chronic heart failure [3] .
OBJECTIVES
The purpose of our study is to analyze the presence of A/G renin genetic polymorphism in heart failure patients, a less discussed aspect in specialized studies.
MATERIAL AND METHOD
This study was performed on 83 subjects admitted in the Rehabilitation Hospital Cluj- [4] and 40 subjects without cardiovascular disease [control group]. The mean age in patients with chronic heart failure was 64.96 ± 13.19 years and 69.76% of them were men. For all patients the cardiovascular risk factors were assessed, as well as NT-proBNP (normal value being exclusion criteria) in all patients and also they were assessed for the presence of cardiovascular risk factors. In adults, overweight was defined as a body mass index (BMI) from 25 to 29 kg/m 2 and obesity as a BMI ≥30 kg/m 2 [5] . Levels of NTproBNP were measured using the BNP Fragment EIA kit (Biomedica; Vienna, Austria).
We examined polymorphisms the G/AI 9-83 transition in intone 8 of the renin gene (REN). The REN genes were amplified by polymerase chain reaction (PCR) using the following pairs of primers (method described by Rupert, which was modified in the biochemistry laboratory from "Iuliu Haţieganu" University of Medicine and Pharmacy, Cluj-Napoca) [6, 7] : An amount of 25 ng genomic DNA was amplified in a total volume of 25 µl, containing 0.2 µM of each primer, 2.0 mM MgCl 2 , 200 mM dNTPs, 2 U Taq DNA polymerase and 10 × buffer supplied with the enzyme. All reagents were from Fermentas, except for the primers, which were from Eurogentec. The PCR program comprised of an initial denaturation of 10 min at 95°C, followed by 35 cycles of 30 s at 94°C, 30 s annealing at 66°C, 1 minute 30 s elongation at 72°C, followed by a final extension of 2 min at 72°C [7] . The variants were detected by enzymatic digestion with MboI. Homozygotes and heterozygotes were discriminated by separation of the digested fragments in 3% agarose gel electrophoresis. The sizes of the wild type and mutated alleles were as follows: wild type 18-83A allele: 250 bp fragment; mutated 18-83G allele: 171 and 79 bp fragments.
The size of the PCR and digested products were checked by electrophoresis in 3% agarose gel stained with 10 mg/ml ethidium bromide ( fig. 1 ) [7] . 83A/G-REN genotypes. Lane 1,2,4,5,8: heterozygotes 83A/83G fragments of 250, 171 and 79 bp; lane 3,6,7,9: negative83A/83A fragments of 250 bp; lane 10: pBR HaeIII digest DNA molecular marker.
All medical assessments were performed on the first day of hospitalization of congestive heart failure patients before starting specific treatment. All investigations were also made for 40 healthy subjects.
The local institutional Ethics Committee approved the study and all participants gave their written informed consent.
Statistical analysis was carried out using SPSS for Windows 16.0 and MedCalc 10.3.0.0 software programs. The analysis of the differences between qualitative variables was performed by using the χ2 test. Mean differences among continuous qualitative variables were evaluated with the Student's t-test (unpaired and paired), while nonparametric tests (Mann-Whitney U) were used to assess distribution variables that did not comply with normal conditions. A value of P < 0.05 was deemed statistically significant.
RESULTS
The characteristics of the patients and the subjects without cardiovascular disease are summarized in Table I . Heart failure etiology was ischemic in 60.46 % of patients. The average value of NT-pro BNP was 2991.24 ± 2034.6 pg/ml in accordance to ESC guideline criteria from 2008, for a certain diagnosis of chronic heart failure [5] . As it was expected, heart failure patients presented low lipid fraction values: Cholesterol = 162.36 ± 38.28 mg/dl, LDL-Co = 104.88 ± 27.60 mg/dl, Triglycerides = 109.12 ± 55.84 mg/dl, HDL-Co = 35.68 ± 9.55 mg/dl.
A/G renin genetic polymorphism distribution in heart failure patients with pathogenic potential was of 60.46% (homozygote form 4.65% and heterozygote form 55.81% as it is shown in figure  2) . Distribution of REN A/G genetic mutation in heart failure patients with hypertension, obesity and diabetes mellitus is presented in Table II . The mean age in the control group was 48.33 ± 10.24 years. There were 32.5% men and 67.5% women. None of them presented the homozygote form of REN A/G mutation.
In return, the heterozygote form was detected in 37.5% of control patients who all were diagnosed with different grades of obesity or overweight. We determined χ2(2.616) and p value (0.106), which show no statistically significant difference between REN A/G mutation in patients with chronic heart failure and those without chronic heart failure. We obtained the same result by using the Z-test: two samples for means with a p value of 0.124. Renin-angiotensin inhibitors therapy is undoubtedly of first choice in patients with heart failure. This therapy was administered to 81.39% of them, as follows: 69.76% received angiotensinconverting enzyme inhibitors (ACEI) and 11.62% received angiotensin receptor blockers (ARB's). 73.07% of patients with REN A/G pathogenic mutations were treated with ACEI and ARB's were prescribed only to 5.2% of them.
DISCUSSION
Despite all complex existing treatments, chronic heart failure remains a threatening public health issue. It is estimated that in developed countries 1-2% of adults suffer from chronic heart failure. More so, the percentage exceeds 10% in population over 70 years [8] . The association between high plasma levels of renin and cardiovascular disease was described for the first time in 1972 when Brunner et al. [9] showed a direct relationship between circulating renin, myocardial infarction and stroke event risk in patients with hypertension. During the following years, the involvement of renin in cardiovascular disease pathogenesis was extensively studied. In 1997, Alderman et al. [10] studied 1717 hypertensive subjects and had the same findings as Brunner, except for the correlation between high renin levels and stroke events. Framingham Heart study reported that high renin value increases general mortality in the first 3 years after the admission of 3298 patients with or without hypertension. However, this research observed no correlation between renin levels and ischemic heart disease [11] . Still, the authors do not exclude the possible implication of excessive renin secretion in the appearance of subclinical ischemic heart disease [11] . A high number of studies have associated renin with hypertension pathogenesis due to its decisive role in the renin-angiotensinaldosterone system [RAS] functionality. Renin cuts the glycosylated form of angiotensinogen into angiotensin I [12] , which in turn is converted into angiotensin II by angiotensin-converting enzyme [ACE] and kinase proteins. Angiotensin II has a great influence on hypertension and ischemic heart disease pathogenesis by exerting its main effects via different types of receptors, especially AT1. Current research has shown that high plasma levels of renin increase general risk of mortality in patients diagnosed with chronic heart failure [13] [14] [15] . This important risk was also observed in asymptomatic patients with left ventricular dysfunction [16] . In addition, high circulating renin may be responsible for the development and enhancement of heart failure. Undoubtedly, the whole reninangiotensin-aldosterone system is involved.
Therefore, current studies try to unravel the exact mechanisms by which each component of RAS system reaches high plasma levels in patients diagnosed with cardiovascular disease, diabetes mellitus or metabolic syndrome [12] . According to these findings, it has been established that genetic mutations lead to an excessive renin secretion or to AT receptors structure modifications. Renin genetic mutations have been previously studied, especially in patients with hypertension and less in subjects with heart failure. Actually, its gene (REN) plays a crucial role in the pathogenesis of essential hypertension and cardiovascular disease [17] . Most studies have focused on highlighting the A allele of single nucleotide polymorphisms (SNP) rs66939554 and rs6696954A [18] and also the 10607A and 12057T mutations. However, new studies are required in order to have relevant data related to renin genetic mutations in heart failure patients.
Our study showed that REN genetic mutations were found in 60.46% of heart failure patients in comparison with 37.5% of control subjects, this difference being without any statistical significance. The heart failure lot contained 38.46% patients suffering from hypertension and renin gene polymorphism. Interestingly, there was a big number [55.88%] of obese and overweight heart failure patients who presented renin gene polymorphism. Moreover, in all control subjects with obesity REN gene mutations were found. To date, no data concerning the association between high levels of renin and obesity has been reported, although further investigations are needed to define its indepth mechanisms. A possible explanation would be that excessive renin secretion may determine extensive angiotensinogen release, which in turn increases the angiotensin I and II levels. Angiotensin II may have a key role to play in the conversion of preadipocytes into adipocytes [19] . Angiotensin-converting enzyme (ACE) was found in the adipose tissue, too [20] . In this study 20.9% of patients suffered from both heart failure and diabetes mellitus. Concerning this issue, studies speculate that renin-angiotensin-aldosterone system increases insulin resistance [21] . As shown above, all patients diagnosed with heart failure had significantly high levels of NT-proBNP [over 2000 pg/ml], in accordance with ESC guide [4] . A recent study performed in Japan (2011) by Nishiyama et al. observed a strong and direct correlation between BNP and renin levels in patients with dilatative cardiomyopathy and heart failure. Furthermore, they suggested that those two parameters interact physiologically [22] . As we were expecting, heart failure patients presented low lipid fraction values. It is postulated that low lipid fraction levels suggest a bad prognosis for end-stage heart failure patients and at the same time they represent strong risk factors for mortality in these individuals [23] [24] [25] [26] . Congestive hepatopathy occurs in an advanced chronic heart failure and leads to low plasma lipid fraction levels. It is also noted that intestinal endotoxins may translocate the swollen mucosa and cause the release of cytokines. The endotoxin or lipopolysaccharide is a toxic component of gram-negative bacterial wall which typically consists of a lipid A and a O polysaccharide. As it is well known, inflammation is as a key player in chronic heart failure which involves a variety of proinflammatory cytokines such as TNFα, IL-6, IL-1 and soluble receptors of TNF α-sTNFR-I and sTNFR-II. Plasma lipoproteins exert specific and selective effects on endotoxins by binding and neutralizing them. In this way the inflammatory cascade is blocked. Thus, low lipid fraction values are direct associated with end-stage heart failure, which may be easily explained. According to the ESC guidelines [4, 8] , ACEI and ARB's were administered to most of the heart failure patients, chiefly to those with REN genetic polymorphisms. Most studies reported that finding REN genetic polymorphisms in subjects without cardiovascular disease might signify a high mortality risk factor [11, 17, 27] .
CONCLUSION
Although REN genetic polymorphisms was much more frequently found in patients with heart failure compared to healthy subjects, the current study could not demonstrate the involvement of A/G renin polymorphisms in the pathogenesis of congestive heart failure. More research including a larger number of patients with this pathology is required.
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